EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world monitoring strategies and predictors guiding the transition from active surveillance to treatment in ISUP 1 prostate cancer

Giulia Giannini, Amer Mousa, Eberhard Steiner, Nastasiia Artamonova, Mona Kafka, Isabel Heidegger

Journal of Cancer Research and Clinical Oncology · 04.03.2026 · 152 (3)

DOI: 10.1007/s00432-026-06441-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, online erschienen am 04.03.2026. Verfasst von Giulia Giannini und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Medical University of Innsbruck, Anichstreet 35, 6020, Innsbruck, Austria. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Watchful Waiting. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Innsbruck and Medical University of Innsbruck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Active surveillance (AS) is the standard approach for managing ISUP 1 prostate cancer (PCa), ensuring oncological safety while minimizing overtreatment. However, AS protocols vary significantly. This study assessed a structured AS protocol incorporating PSA kinetics, multiparametric MRI (mpMRI), and targeted biopsies to identify predictors of treatment transition.

Methods

We retrospectively reviewed 89 patients with ISUP 1 PCa managed with AS between 2010 and 2024. Inclusion criteria were PSA < 10 ng/mL and ≤ 2 positive biopsy cores with ≤ 50% tumor involvement per core. Patients underwent regular PSA testing, mpMRI, and risk-adapted biopsies. Outcomes included treatment conversion, progression predictors, and the role of mpMRI.

Results

Median follow-up was 52.8 months. PSA was monitored at a median interval of 4.8 months, and mpMRI every 15.7 months (median). At diagnosis, 68.5% underwent mpMRI, with PIRADS 4 as the most frequent. During AS, 66.3% underwent at least one re-biopsy, most commonly triggered by PSA progression (73%). Treatment was initiated in 37.1% after a median of 37.9 months due to PSA progression (54.5%), mpMRI changes (21.2%), combined PSA/mpMRI findings (6.1%), histological upgrading (9.1%), or patient preference (3%). Treatments included radical prostatectomy, EBRT or LDR brachytherapy. Among these patients, no PSA persistence was observed; biochemical recurrence occurred in 6.1%, metastases in 4.0%, and overall mortality in 4.5%, with no PCa-specific deaths.

Conclusion

A structured, risk-adapted AS protocol using PSA kinetics and mpMRI enabled personalized management and timely detection of progression. These findings support the standardization of AS protocols, which should be validated in larger cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsWatchful WaitingHumansMaleRetrospective StudiesAgedProstate-Specific AntigenMiddle AgedMultiparametric Magnetic Resonance ImagingDisease ProgressionFollow-Up Studies

Stichwörter der Autor:innen

Active surveillanceISUP 1MonitoringPredictors for active therapyProstate cancerReal world setting

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, Medical University of Innsbruck, Anichstreet 35, 6020, Innsbruck, Austria.
  • Department of Urology, Medical University of Innsbruck, Anichstreet 35, 6020, Innsbruck, Austria. isabel.heidegger@tirol-kliniken.at.

Förderung

  • University of Innsbruck and Medical University of Innsbruck

Zitieren

APA

Giannini, G., Mousa, A., Steiner, E., Artamonova, N., Kafka, M., & Heidegger, I. (2026). Real-world monitoring strategies and predictors guiding the transition from active surveillance to treatment in ISUP 1 prostate cancer. Journal of Cancer Research and Clinical Oncology, 152(3). https://doi.org/10.1007/s00432-026-06441-9

Vancouver

Giannini G, Mousa A, Steiner E, Artamonova N, Kafka M, Heidegger I. Real-world monitoring strategies and predictors guiding the transition from active surveillance to treatment in ISUP 1 prostate cancer. Journal of Cancer Research and Clinical Oncology. 2026;152(3). doi:10.1007/s00432-026-06441-9

BibTeX
@article{Giannini2026,
  author = {Giannini, Giulia and Mousa, Amer and Steiner, Eberhard and Artamonova, Nastasiia and Kafka, Mona and Heidegger, Isabel},
  title = {Real-world monitoring strategies and predictors guiding the transition from active surveillance to treatment in ISUP 1 prostate cancer},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2026},
  volume = {152},
  number = {3},
  doi = {10.1007/s00432-026-06441-9}
}
Kostenlos starten →